Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Bacterial Infections
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Bacterial Infections
    TopAbstracts in Bacterial Infections 11/24/2008 - (DGNews)
    Efficacy of percutaneous versus intradermal BCG in the prevention of tuberculosis in South African infants: randomised trial - (BMJ)
    Swissmedic Approves Ceftobiprole Medocaril for Treatment of Complicated Skin Structure Infections - (DGNews)
    Extensively drug-resistant tuberculosis in the United States, 1993-2007 - (JAMA)
    Five-Day Moxifloxacin Can Provide Benefits for Acute Bacterial Sinusitis: Presented at ACAAI - (DGDispatch)

    News archive

     Recent webcasts/CME - Bacterial Infections
      Emergence of Methicillin-Resistant Staphylococcus aureus
      Adolescent Immunization Update Opportunities to Prevent Pertussis, Meningococcal Disease, and HPV
      MRSA And Diabetic Foot Wounds: Where Do We Go From Here?
      C. difficile - A Community Epidemic
      Pulmonary Complications of Anti-Tumor Necrosis Factor-a Therapy

      Webcasts/CME archive

       Recent cases - Bacterial Infections
        A Simple Hepatic Cyst with Elevated Serum and Cyst Fluid CA19-9 Levels: A Case Report
        Diagnostic Difficulties of Lactobacillus casei bacteraemia in Immunocompetent Patients: A Case Report
        Acute Myocardial Infarction and Pulmonary Tuberculosis in a Young Female Patient: A Case Report
        Necrotizing Fasciitis with Toxic Shock Syndrome in a Child: A Case Report and Review of Literature
        A Rare Case of Embolic Spondylo-Discitis After Treatment of Aortic Valve Endocarditis

        Cases archive
          




        my personal edition > bacterial infections > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        SENTRY Programme Detects Decreasing Susceptibility to Levofloxacin and Macrolides in European Countries: Presented at ECCMID-ICC

        By Chris Berrie

        MUNICH, GERMANY -- April 2, 2007 -- Pathogens associated with community-acquired respiratory tract infections (CA-RTIs) -- Haemophilus influenzae and Moraxella catarrhalis -- show relatively stable, but variable, antimicrobial resistance patterns across 13 European countries that are being monitored in the SENTRY Antimicrobial Surveillance Programme.

        However, Streptococcus pneumoniae resistance rates for penicillin, macrolides and to a lesser extent fluoroquinolones continue to evolve with varying velocities.

        These data from 10 years of monitoring in the SENTRY Programme were presented here by Ronald M. Jones, MD, principal investigator, president and chief executive officer, JMI Laboratories, North Liberty, Iowa, United States, here at the 17th European Congress of Clinical Microbiology and Infectious Diseases and 25th International Congress of Chemotherapy (ECCMID-ICC).

        "The programme itself is actually the most comprehensive antimicrobial surveillance programme in the World," with more than 100 participating medical centres worldwide, 25 to 30 of which are in Europe, he said during his presentation on March 31st.

        The isolates were collected according to site of infection, including for CA-RTIs, bacteraemia, pneumonia in hospitalised patients, skin/ wound infections and urinary tract infections.

        The objective of this analysis was to determine the antimicrobial susceptibility patterns and beta-lactamase occurrence for S. pneumoniae, M. catarrhalis and H. influenzae from CA-RTI samples collected from these 13 European countries between 1997 and 2006.

        These samples were forwarded annually to a central reference laboratory where the susceptibility tests were performed and where the organism's identity was confirmed. A panel of 55 antimicrobials have been monitored according to Clinical and Laboratory Standards Institute methods, providing the trends in the susceptibility rates by country through a total of 6,280 samples of H. influenzae, 1,908 M. catarrhalis and 6,753 S. pneumoniae.

        For H. influenzae, the resistance to ampicillin, as beta-lactamase positive (BL+) rate, varied from 3.6% to 30.8%, with beta lactamase-negative ampicillin-resistant H. influenzae strains found in 6 countries (13-country mean, 0.3%; 0.5%-1.7%). Among the BL+ strains, resistance to amoxicillin with or without clavulanate was rare and seen in only 2 countries (13-country mean, 0.03%; 2.5%-5.5%). Dr. Jones also indicated that the susceptibility rates for H. influenzae were generally greater than 90% for the range of key antimicrobials.

        M. catarrhalis showed susceptibility to nearly all classes of antimicrobials, although while the macrolides, tetracyclines, and enzyme-stable beta-lactams remained very potent, there was a rare high-level resistance to fluoroquinolones. These isolates also had a uniform beta-lactam production rate and associated penicillin resistance (mean, 95.5%; range, 92%-100%) across the full 13 countries.

        Relatively high susceptibilities were generally seen for S. pneumoniae across a range of selected antimicrobials (range, 67%-98%). For penicillin and erythromycin, the 13-country, 10-year mean rates of susceptibility were 70.1% and 71.5%, respectively, although Dr. Jones did stress the potential for increased susceptibility for penicillin (~97%) should the new, proposed breakpoint for CA-RTI of less than or equal to 2 mg/L be applied.

        In comparing these penicillin and erythromycin susceptibilities directly, over the 3 most recent years of sampling, 7 countries showed equal rates, while Germany, Belgium and Italy showed higher penicillin rates, and Ireland, Turkey and Israel, higher erythromycin rates. "This will be related to what the usage patterns of these drugs are in those nations," Dr. Jones said.

        Thus, consistent monitoring of these European CA-RTI pathogens through the SENTRY Programme showed that susceptibilities towards penicillin have been variable across these European countries. However, macrolide susceptibility has predominantly decreased, and, of note, levofloxacin susceptibility has decreased, with the detection of resistant strains seen.

        While Dr. Jones indicated the disturbing resistances seen in beta lactamase-negative ampicillin-resistant with H. influenzae and for fluoroquinolones with M. catarrhalis, he stressed that local surveillance of these RTI pathogens continues to be required to provide the best selections of empiric treatments, "Although they should probably be done more often and on a country basis," he added.

        The SENTRY Programme has been supported collectively by Elan, Schering-Plough, Pfizer, Wyeth, Cubist, Johnson & Johnson, Abbott, GlaxoSmithKline, and AstraZeneca.


        [Presentation title: Community-Acquired Respiratory Tract Infections in Europe Caused by S. Pneumoniae, H. Influenzae and M. Catarrhalis: Report From 10 Years of Monitoring by the SENTRY Programme. Abstract O29]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send